Market News

HIMS Soars on Q3 Beat; Impressive Guidance

Shares of telehealth platform operator Hims & Hers Health (NYSE:HIMS) are soaring high in the pre-market session today after the company posted impressive third-quarter numbers.

Revenue surged a massive 95.3% year-over-year to $144.84 million, cruising past estimates by $14.5 million. Net loss per share at $0.09 too came in narrower than expectations by $0.01.

The company’s focus on consumers helped it net over 100,000 net new subscriptions during this period, taking the total tally to 991,000 subscriptions at the end of Q3.

Further, buoyed by scale and operating leverage, the company has upped its full-year outlook and expects adjusted EBITDA profitability in the fourth quarter.

For the full-year 2022, revenue is anticipated between $519 million and $522 million. Adjusted EBITDA loss is expected to hover between $20 million and $18 million.

Further, adjusted EBITDA for the fourth quarter is seen landing between $0 million and $2 million.

Read full Disclosure

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More